

# Lithium-induced reduction in urinary concentrating ability and urinary aquaporin 2 (AQP2) excretion in healthy volunteers

ROBERT J. WALKER, SUSAN WEGGERY, JENNIFER J. BEDFORD, FIONA J. MCDONALD, GAYE ELLIS, and JOHN P. LEADER

*Department of Medical & Surgical Sciences, University of Otago, Dunedin, New Zealand; and Department of Physiology, University of Otago, Dunedin, New Zealand*

## Lithium-induced reduction in urinary concentrating ability and urinary aquaporin 2 (AQP2) excretion in healthy volunteers.

**Background.** Lithium therapy is associated with the development of nephrogenic diabetes insipidus. Experimentally, lithium inhibits arginine vasopressin (AVP)-stimulated translocation of cytoplasmic aquaporin 2 (AQP2) to the apical membrane. Clinically, the actions of lithium on renal tubular function are less clearly established. This study examined the effects of four weeks of lithium therapy on desmopressin (dDAVP)-stimulated urinary concentrating ability in healthy volunteers.

**Methods.** Eleven healthy volunteers underwent baseline urinary concentrating ability studies which were repeated following 4 weeks therapy with lithium carbonate (250 mg twice a day). Urinary osmolality, urinary AQP2 and cyclic adenosine monophosphate (cAMP) levels were measured following overnight fluid deprivation and after the administration of 40 µg of dDAVP. Baseline values were compared with results after 4 weeks of lithium therapy.

**Results.** Four weeks of lithium therapy reduced dDAVP-stimulated urinary concentrating ability ( $996 \pm 27$  to  $945 \pm 26$  mOsm/kg) ( $P < 0.05$ ) and this was associated with significant reduction in urinary AQP2 excretion ( $99.2 \pm 10.0$  to  $77.8 \pm 7.4$  fmol/µmol creatinine) ( $P < 0.05$ ) and urinary cAMP excretion ( $3188 \pm 376$  to  $2212 \pm 378$  units) ( $P < 0.01$ ).

**Conclusion.** Four weeks of lithium therapy in healthy volunteers produced a small but significant reduction in dDAVP-stimulated urinary concentrating ability, which appears to be mediated by the inhibition of AVP-stimulated translocation of cytoplasmic AQP2 to the collecting tubule apical membrane via inhibition of adenyl cyclase.

Lithium therapy is a major therapeutic agent used to treat patients with various mood disorders. However, it has been associated with several different forms of renal injury. In an analysis of several studies published

from 1979 to 1986, comprising 1172 patients [1], the most prevalent renal effect of lithium was impairment of renal concentrating ability, which was estimated to be present in at least 54% of 1105 unselected patients on chronic lithium therapy. This defect translated into overt polyuria and polydipsia in up to 20% of unselected cases [1]. Initially, the decreased urinary concentrating ability is largely reversible following cessation of lithium. Of greater concern is the development of a progressive impairment of urinary concentrating ability [nephrogenic diabetes insipidus (NDI)] in patients on long-term maintenance lithium therapy, which is resistant to the actions of arginine vasopressin (AVP) (antidiuretic hormone). This functional lesion is not usually reversible and is associated with a chronic focal interstitial fibrosis in renal biopsy [2, 3]. The lithium-induced interstitial fibrosis may be progressive leading to end-stage renal failure [3].

The ability of the mammalian kidney to produce a concentrated urine is the function of two processes. First, there is the creation of a hyperosmotic medullary interstitium, and second there is the insertion of aquaporins into the apical [aquaporin 2 (AQP2)] and basolateral membranes (AQP3 and AQP4) of the collecting tubules to allow the reabsorption of water down a concentration gradient. Of these, AQP2, confined to the apical regions of the principal cells of the collecting tubules, is the primary target for short-term regulation of collecting duct permeability by the antidiuretic hormone (AVP) [4, 5]. Failure of such regulation, which may occur as a result of a number of pathophysiologic conditions, leads to disorders of water balance, manifest clinically by an inability to concentrate the urine with associated nocturia and polyuria [4, 5]. If not controlled, this has the ability to further compromise renal function.

Lithium is likely to enter collecting duct cells via the lumenally located epithelial sodium channel (ENaC) since this channel has a higher permeability for lithium compared to sodium (reviewed in [6]). Once inside collecting duct cells, lithium influences both sodium and water handling pathways. Chronic lithium treatment in

**Key words:** lithium, urinary aquaporin 2, human studies, urinary concentrating ability.

Received for publication June 1, 2004

and in revised form July 19, 2004

Accepted for publication August 9, 2004

© 2005 by the International Society of Nephrology

rats reduces amiloride-sensitive (ENaC) sodium current and increases urinary sodium excretion [7]. This appears to be due to down-regulation of ENaC subunit proteins within the cells of the cortical and outer medullary collecting duct [8]. A number of different mechanisms may be involved in lithium-induced changes in tubular cell water permeability. Briefly, lithium inhibits AVP-stimulated translocation of cytoplasmic AQP2 to the apical membrane. This may be due to lithium competing with magnesium, inhibiting magnesium-dependent proteins that activate AVP-sensitive adenylyl cyclase [9]. AVP binds to its  $V_2$  receptor stimulating adenylyl cyclase and cyclic adenosine monophosphate (cAMP) formation, which activates protein kinase A. Protein kinase A phosphorylates cytoplasmic AQP2, which is essential for its translocation and insertion into the apical membrane. Insertion of AQP2 into the apical membrane then allows water permeability and reabsorption in the cortical collecting tubule. Failure of AQP2 insertion leads to an excess of water delivered to the medullary tubule, which exceeds the tubules capability to reabsorb water [4, 5]. The net effect is polyuria.

Although there have been a number of experimental studies investigating the actions of lithium, we report the first study investigating the acute short-term (4 weeks) effects of lithium therapy on urinary AQP excretion and water concentrating ability in healthy volunteers. The aim of this study was to measure the changes in AVP-stimulated urinary concentrating ability and urinary AQP excretion following 4 weeks of lithium carbonate therapy. Baumgarten et al [10] have shown measurement of urinary AQP2 excretion to be a useful approach to study urinary concentrating defects and we have confirmed the validity of urinary AQP measurement in response to water deprivation and desmopressin (dDAVP) administration in normal volunteers [11].

## METHODS

Eleven healthy volunteers (seven males and four females), with no known medical problems and taking no medication, whose ages ranged from 20 to 63 years took part in the study, after giving written informed consent. The study was approved by the Otago Ethics Committee. Participants' demographic data are presented in Table 1. Following baseline studies of urinary concentrating ability, each participant took lithium carbonate 250 mg twice a day for 28 days. The urinary concentrating ability study was then repeated.

### Clinical studies

Following an overnight 12-hour fluid restriction, subjects presented to the Clinical Research Area (Department of Medicine). Height and weight was recorded. Baseline blood samples for plasma osmolality, sodium, creatinine, lithium, and AVP were taken. Baseline urine

**Table 1.** Demographics of participants

Age	Mean 36.5 years (range 20–63 years)
Male:female	7:4
Plasma creatinine	Mean 85 $\mu\text{mol/L}$ (range 67–104 $\mu\text{mol/L}$ )
Lithium concentrations at completion of 4 weeks	Mean 0.45 mmol/L (range 0.3–0.8 mmol/L)


was collected and analyzed for creatinine, AQP2, cAMP levels, and osmolality. Subjects then received a standard dose of 40  $\mu\text{g}$  dDAVP (a synthetic analogue of AVP) intranasally. Water intake was restricted to 500 mL over the next 6 hours. All urine passed was collected and aliquots analyzed for urinary creatinine, osmolality, AQP2, and cAMP levels.

Plasma osmolality, creatinine, lithium, and sodium as well as urinary osmolality and creatinine were measured by standard automated laboratory assays (Healthlab Otago, Dunedin Hospital, New Zealand).

Urinary cAMP was assayed using a cAMP kit supplied by BIOTRAK Assay System (code RPA 509; Amersham Life Sciences, Sydney, Australia) and plasma AVP was measured by an in-house radioimmunoassay [12] (Endolab) (Christchurch Hospital, Christchurch, New Zealand).

Urinary AQP2 levels were measured using a validated chemiluminescent assay [11]. Briefly, 15 mL of urine was spun ( $500 \times g$ ) for 10 minutes to remove cell debris and the supernatant was then concentrated in a Centriplus YM 10 (Amicon, Millipore, Bedford, MA, USA) filter following the manufacturer's instructions. Laemmli loading buffer was added to the samples in the ratio of 2:1 and the samples denatured at  $95^\circ\text{C}$  for 5 minutes. Samples equivalent to 4  $\mu\text{mol}$  urine creatinine were applied to membranes [Immobilon polyvinylidene difluoride (PDVF) (Millipore, Bedford, MA, USA) in a BioDot apparatus (Bio-Rad, Hercules, CA, USA)]. The membranes were blocked for 1 hour in 5% nonfat dried milk in Tris-buffered saline (TBS) [200 mmol/L Tris, 73 mmol/L NaCl, pH 7.6, with 1% Tween 20 (vol/vol)]. After washing, the membranes were incubated overnight at  $4^\circ\text{C}$  with 1:2500 dilution of rabbit antiserum raised against a synthetic peptide made from the C-terminal end of human AQP2 (amino acids 257-271 VELH-SPQALPRGTKA) (Chiron Mimetopes, Melbourne, Australia). After further washing, the membranes were incubated in the secondary antibody at 1:3000 dilution of goat antirabbit IgG coupled to horseradish peroxidase (HRP) (DAKO, PO488, Glostrup, Denmark). Antigen-antibody reactions were detected by enhanced chemiluminescence (Supersignal West Pico; Pierce, Rockford, IL, USA) according to the protocol supplied by the manufacturer.

In order to quantitate the amounts of AQP2 in the urine, synthetic peptide (Chiron Mimetopes, Melbourne) was cross-linked to bovine serum albumin using a protein-protein cross linking kit (P6305) (Molecular Probes,



**Fig. 1. Changes in urine osmolality.** Responses to overnight water deprivation and administration of desmopressin (dDAVP) (40  $\mu\text{g}$  intranasally) before and after 4 weeks lithium therapy in healthy volunteers ( $N = 11$ ). Data mean  $\pm$  SEM. \* $P < 0.05$ ; \*\* $P < 0.01$  compared to 0 weeks.


Eugene, OR, USA). Membranes were prepared as outlined above, with the cross-linked synthetic peptide used as a standard. The resulting x-ray film was scanned densitometrically (GS-700) (BioRad) and analyzed using Molecular Analyst software. A standard curve (serial dilutions of the peptide) using the cross-linked protein versus densitometric readings was made. Urinary AQP2 levels are expressed in terms of urinary creatinine levels.

### Statistics


Values are mean  $\pm$  SEM, R values and statistical values were calculated with Kaleidograph (Synergy Software, Reading, PA, USA).

### RESULTS

All 11 subjects completed the study, with no reported side effects. All subjects achieved a plasma lithium concentration that would be acceptable in standard clinical practice (Table 1). Plasma lithium levels remained stable over the 4-week period (data not shown). The results clearly demonstrate a significant reduction ( $P < 0.05$ ) in AVP-stimulated urine osmolality after 4 weeks of lithium therapy (Fig. 1). Urine osmolality 4 hours post-dDAVP fell from  $996 \pm 27$  mOsm/kg to  $945 \pm 26$  mOsm/kg ( $P < 0.05$ ). The reduction in urinary concentrating ability was associated with a significant reduction in AVP-stimulated AQP2 excretion into the urine (Fig. 2). Urine AQP2 concentrations 4 hours post-dDAVP fell from  $99.2 \pm 10.0$  fmol/ $\mu\text{mol}$  creatinine to  $77.8 \pm 7.4$  fmol/ $\mu\text{mol}$  creatinine, after 4 weeks of lithium therapy ( $P < 0.01$ ). In addition, there was a significant reduction in urinary cAMP excretion (Fig. 3). Urinary cAMP excretion levels at 4 hours post-dDAVP fell from  $3188 \pm 376$  units



**Fig. 2. Changes in urine aquaporin 2 (AQP2) excretion.** Response to overnight water deprivation and administration of desmopressin (dDAVP) (40  $\mu\text{g}$  intranasally) before and after 4 weeks lithium therapy in healthy volunteers ( $N = 11$ ). Data mean  $\pm$  SEM. \* $P < 0.05$ ; \*\* $P < 0.01$  compared to 0 weeks.



**Fig. 3. Changes in urine cyclic adenosine monophosphate (cAMP) excretion.** Response to overnight water deprivation and administration of desmopressin (dDAVP) (40  $\mu\text{g}$  intranasally) before and after 4 weeks lithium therapy in healthy volunteers ( $N = 11$ ). Data mean  $\pm$  SEM. \*\* $P < 0.01$  compared to 0 weeks.

to  $2212 \pm 378$  units ( $P < 0.01$ ). The correlation between urinary AQP2 concentrations and urinary cAMP concentration was highly significant ( $r^2 = 0.82$ ).

The plasma AVP, osmolality, sodium, and creatinine values were unchanged over the duration of the study (Table 2).

### DISCUSSION

This study has demonstrated that lithium carbonate therapy significantly impairs urinary concentrating ability within 4 weeks of initiating therapy in healthy volunteers.

**Table 2.** Plasma measurements taken during the studies of urinary concentrating ability at baseline and after 4 weeks of Lithium therapy (N = 11)

	0 hours	4 hours
Osmolality mOsm/kg		
Baseline	288 ± 1	289 ± 1
4 weeks	289 ± 1	290 ± 1
Creatinine μmol/L		
Baseline	85 ± 4	85 ± 4
4 weeks	90 ± 4	87 ± 4
Arginine vasopressin pmol/L		
Baseline	2.19 ± 0.44	3.10 ± 0.69
4 weeks	3.05 ± 0.77	4.22 ± 0.55

Data mean ± SEM.

At the completion of 4 weeks of therapy, a 6% reduction in urinary osmolality following 40 μg of intranasal dDAVP was associated with a 27% reduction in urinary AQP2 excretion and a 44% reduction in urinary cAMP excretion. The reduction in urinary cAMP excretion would support the observation that lithium is inhibiting the pathway whereby vasopressin leads to trafficking of AQP2 to the apical membrane, as has been demonstrated experimentally. Nielsen et al [4] has demonstrated in animal models that lithium inhibits AVP-stimulated insertion of AQP2 into the apical membrane due to inhibition of adenyl cyclase which is normally activated following binding of AVP to the V<sub>2</sub> receptor.

Rats given lithium in the diet for 35 days, in amounts calculated to be approximately equivalent to the therapeutic dosage in humans, became polydipsic and produced large volumes of dilute urine. AQP2 expression in the kidneys of these rats was markedly reduced as assessed by Western blotting [13, 14]. There was a parallel decrease in AQP2 excretion in the urine, though a selective apical pathway [15]. It is likely that a similar situation occurs in humans.

In the only reported study, investigating the actions of lithium on urinary AQP2 excretion in humans, Pedersen et al [16] recently demonstrated that a single dose of lithium carbonate (600 mg) reduced the antidiuretic effect of hypertonic saline up to 5 hours after ingestion. They did not detect a significant change in urinary AQP2 excretion or urine output following an infusion of hypertonic saline when compared to placebo. Unfortunately, they did not measure urinary cAMP levels to support their conclusion that an acute dose of lithium blunted the antidiuretic effect associated with a hypertonic saline infusion, by inhibiting trafficking of renal AQP2 in healthy humans.

In this group of healthy individuals, the reduction in urinary concentrating ability demonstrated in this short term study, was not sufficient to produce partial NDI according to standard criteria [17] as urinary concentrating ability still exceeded 600 mOsm/kg. However, given the significant changes that were evident even after a short course of therapy, we would postulate that the impact of lithium

would become more apparent with time. The lithium-induced changes in urinary concentrating ability tend to become irreversible, however, the point at which this occurs is currently unknown. It is also not clear if the defect in humans is due solely to alterations in lithium-induced inhibition of AVP-stimulated trafficking of AQP2 to the apical membrane in the principal cells of the collecting tubule. Further clinical studies are clearly required to answer these important questions.

## ACKNOWLEDGMENTS

The research was funded by the National Kidney Foundation of New Zealand, Otago Medical Research Foundation, and the Health Research Council of New Zealand.

Reprint requests to Professor Robert J. Walker, Department of Medical & Surgical Sciences, University of Otago, PO Box 913 Dunedin, New Zealand.

E-mail: rob.walker@stonebow.otago.ac.nz

## REFERENCES

1. BOTON R, GAVIRIA M, BATTLE DC: Prevalence, pathogenesis and treatment of renal dysfunction with chronic lithium therapy. *Am J Kidney Dis* 10:329–345, 1987
2. MARKOWITZ GS, RADHAKRISHNAN J, KAMBHAM N, et al: Lithium nephrotoxicity: A progressive combined glomerular and tubulointerstitial nephropathy. *J Am Soc Nephrol* 11:1439–1448, 2000
3. PRESNE C, FAKHOURI F, NOEL LH, et al: Lithium-induced nephrotoxicity: Rate of progression and prognostic factors. *Kidney Int* 64:585–592, 2003
4. NIELSEN S, FROKIAER J, MARPLES D, et al: Aquaporins in the kidney: From molecules to medicine. *Physiol Rev* 82:205–244, 2002
5. NIELSEN S, KWON TH, FROKIAER J, et al: Key roles of renal aquaporins in water balance and water balance disorders. *News Physiol Sci* 15:136–143, 2000
6. GARTY H, PALMER LG: Epithelial sodium channels: Function, structure, and regulation. *Physiol Rev* 77:359–396, 1997
7. THOMSEN SK, BAK M, SHIRLEY DG: Chronic lithium treatment inhibits amiloride-sensitive sodium transport in the rat distal nephrons. *J Pharmacol Exp Ther* 289:443–447, 1999
8. NIELSEN J, KWON TH, PRAETORIUS J, et al: Segment-specific EnaC downregulation in kidney of rats with lithium-induced NDI. *Am J Physiol* 285:F1198–F1209, 2003
9. TIMMER RT, SANDS JM: Lithium intoxication. *J Am Soc Nephrol* 10:666–674, 1999
10. BAUMGARTEN R, VAN DE POL MHJ, DEEN PMT, et al: Dissociation between urine osmolality and urinary excretion of aquaporin in healthy volunteers. *Nephrol Dial Transpl* 15:1155–1161, 2000
11. AL-DAMEH A, BEDFORD JJ, LEADER JP, et al: Urinary aquaporin-2 levels in healthy volunteers. *Nephrology* 8:139–141, 2003
12. SADLER WA, LYNKEY CP, GILCHRIST NL, et al: A sensitive radioimmunoassay for measuring plasma anti-diuretic hormone in man. *NZ Med J* 96:959–963, 1983
13. KWON TH, LAURSEN UH, MARPLES D, et al: Altered expression of renal AQP2 and Na<sup>+</sup> transporters in rats with lithium-induced NDI. *Am J Physiol* 279:F552–F562, 2000
14. MARPLES D, CHRISTENSEN S, CHRISTENSEN EI, et al: Lithium-induced down regulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. *J Clin Invest* 97:1960–1968, 1996
15. WEN H, FROKIAER J, KWON TH, NIELSEN S: Urinary excretion of aquaporin-2 in rat is mediated by a vasopressin-dependent apical pathway. *J Am Soc Nephrol* 10:1416–1429, 1999
16. PEDERSEN RS, BENTZEN H, BECH JN, et al: Effect of an acute oral lithium intake on urinary aquaporin-2 in healthy humans with and without simultaneous stimulation with hypertonic saline infusion. *Scand J Clin Invest* 63:181–194, 2003
17. BAYLIS PH: Investigation of suspected hypothalamic diabetes insipidus. *Clin Endocrinol* 43:507–510, 1993